AMGEN正式成立香港／澳門團隊

香港2016年8月11日電 /美通社/ -- 全球生物科技巨企Amgen公司，宣佈成立香港／澳門團隊，為本地嚴重疾病患者帶來創新藥品治療。

Amgen正式成立香港／澳門團隊 (左至右：唐嘉其、溫陳佩茜、伍連德)

Amgen進入港澳市場旨在促進本地醫療的發展，為本地重病患者提供創新治療藥物。對於Amgen而言，這也是其全球擴展計劃中非常重要的一環。Amgen日本及亞太區總部也設在香港，同位於香港鰂魚涌太古坊港島東中心。

Amgen一直以服務患者為使命，並致力將先進的科學和生物科技轉化為拯救生命的藥物。Amgen努力為全球患者提供已註冊的藥物產品，並擁有完善的新藥及生物相似製劑研發計劃。

Amgen日本及亞太區副總裁兼總經理溫陳佩茜表示：「Amgen於2007年在香港設立了一個臨床研究辦公室，當時員工少於10人。今天，我們很高興成立了專責香港及澳門業務的團隊。我們預計，今年底香港員工將超過80人，努力爲本地區和日本及亞太區患者服務。」

Amgen目前在香港和澳門的發展計劃包括：

• 與醫療界合作，確保患者可獲得Amgen的藥物治療；
• 推出新研發的藥物，針對的治療領域包括骨骼、心血管、腫瘤、血液、腎臟、炎症及神經疾病等；另外，公司亦有開發生物相似性藥品；
• 積極成為香港與澳門生物科技產業活躍的一員，追求共同成長，塑造有利生物科技產業發展的環境。

為配合業務發展，Amgen最近分別委任了伍連德先生出任東南亞、香港及印度的區域總經理，及唐嘉其先生為香港／澳門地區的總經理。加入Amgen前，他們兩位均任職於跨國製藥公司，並具有20多年的經驗。所以無論是對科研製藥行業或是香港及區內其他市場，兩位均相當熟悉。

唐嘉其說：「公司非常重視香港及澳門的業務，並期望我們的團隊不斷壯大。作爲一家全球領先的生物科技公司，Amgen將會盡力協助促進生物科技產業在區內的發展。」

Amgen最近在全球 48 個國家，取回三項藥品的所有權利。目前合共擁有Prolia® (denosumab)、XGEVA® (denosumab)、Vectibix® (panitumumab)、Neulastim® (pegfilgrastim)及Neupogen® (filgrastim)此五種藥物在香港及澳門市場的銷售許可。此外，Amgen也已獲香港衞生署批准，銷售Repatha® (evolocumab)。

Amgen是極具規模的跨國生物製劑生產商，為患者提供優質藥物，一直以來，表現卓越。Amgen總部位於美國加州千橡樹市 (Thousand Oaks)，公司十分重視亞太市場的發展，現已在全球超過 100 個市場設有營運據點，其中包括澳洲、紐西蘭、中國內地、香港、澳門、印度、日本、韓國、新加坡、台灣、泰國等。

Amgen簡介

Amgen一直致力為人類探索、開發、製造和提供嶄新的藥物，開拓生物科技的潛能，為嚴重疾病患者找尋新的治療方案；並運用先進的人類遺傳學知識，解構疾病背後複雜的病理，瞭解人類生物學的基礎。

Amgen鎖定現時仍欠缺有效治療的疾病領域為目標，靠著其對生物製劑的認識，努力不懈尋求新的解決方案以改善醫療健康，大幅改善人類生活。Amgen已從 1980 年代的生物科技先驅，晉身成為一家領先全球的生物科技公司，為全球數百萬患者服務，持續研發更多具有開創性潛力的藥物。

詳細資訊請瀏覽Amgen總公司網頁：ww.amgen.com。

Forward-Looking Statements

This news release contains forward-looking statements that involve significant risks and uncertainties, including those discussed below and others that can be found in our Form 10-K for the year ended Dec. 31, 2015, and in any subsequent periodic reports on Form 10-Q and Form 8-K. Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

No forward-looking statement can be guaranteed and actual results may differ materially from those we project. The Company's results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments (domestic or foreign) involving current and future products, sales growth of recently launched products, competition from other products (domestic or foreign), and difficulties or delays in manufacturing our products. In addition, sales of our products are affected by reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment as well as U.S. legislation affecting pharmaceutical pricing and reimbursement. Government and others' regulations and reimbursement policies may affect the development, usage and pricing of our products. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our products after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors. We depend on third parties for a significant portion of our manufacturing capacity for the supply of certain of our current and future products and limits on supply may constrain sales of certain of our current products and product candidate development. In addition, we compete with other companies with respect to some of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock.

媒體查詢：
愛德曼公關：AmgenHK@edelman.com 電話：+852 2804 1338
或Mary Klem：mklem@amgen.com（只提供英文查詢）

圖片 - http://photos.prnasia.com/prnh/20160811/8521605117